Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, James N. Kochenderfer, Jesús G. Berdeja et al.|New England Journal of Medicine|2019Cited by 1.7k
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialAlfons JM van den Eertwegh, Winald R. Gerritsen, Jurjen Versluis et al.|The Lancet Oncology|2012Cited by 357
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancerKristen Hege, Stephen A. Sherwin, Carl H. June et al.|Journal for ImmunoTherapy of Cancer|2017Cited by 320
A Clinical Development Paradigm for Cancer Vaccines and Related BiologicsAxel Hoos, Geoffrey Nichol, Giorgio Parmiani et al.|Journal of Immunotherapy|2006Cited by 271